{"text": "This is a randomised , controlled , open , two - armed , two - period cross - over , multi - centre phase II / III study to assess the safety , tolerability and pharmacokinetics of once - daily oral modified - release hydrocortisone in comparison to conventional thrice - daily oral hydrocortisone tablets in patients with adrenal insufficiency .", "label": "", "metadata": {}, "score": "31.104195"}
{"text": "There is limited experience with doses beyond 800 mg / day .If the antihypertensive effect measured at trough using once - daily dosing is inadequate , a twice - a - day regimen at the same total daily dose or an increase in dose may give a more satisfactory response .", "label": "", "metadata": {}, "score": "31.143997"}
{"text": "Patients receiving oral administration of soft - gelatine capsule of Nintedanib 150 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 30 mg was given continuously once daily ( q.d . ) .", "label": "", "metadata": {}, "score": "36.616493"}
{"text": "To view content sources and attributions , please refer to our editorial policy .The purpose of this study is to evaluate the multiple dose pharmacokinetics of 2 Canagliflozin / extended release Metformin ( CANA / MET XR ) fixed dose combination tablets ( 150 mg/1,000 mg each ) following once - daily oral dosing in healthy participants .", "label": "", "metadata": {}, "score": "36.945457"}
{"text": "Comparison of Overall Patient Tolerability Score Between Once Daily and Thrice Daily Therapy , Assessed by Patient and Investigator - Part A [ Time Frame : 12 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "37.376144"}
{"text": "The total duration of the study will be about 42 days for each participant .During the Open - Label Treatment Phase , approximately 12 healthy adult participants will receive a single oral dose of 2 CANA / MET XR tablets once daily for 7 days after a provided dinner .", "label": "", "metadata": {}, "score": "37.908333"}
{"text": "Detailed Description : .This is an open - label ( physicians and participants know the identity of the assigned treatment ) , multiple - dose , single - center , pharmacokinetic study of a fixed dose combination ( FDC ) of 150 mg/1,000 mg Canagliflozin / extended release Metformin ( CANA / MET XR ) tablets .", "label": "", "metadata": {}, "score": "38.50717"}
{"text": "Table includes only participants with both baseline and post baseline values .Reporting Groups .Description .Placebo .Each participant received matching placebo once daily for 18 weeks with protocol - specified doses of metformin alone or metformin plus sulphonylurea .", "label": "", "metadata": {}, "score": "38.98005"}
{"text": "A lower value corresponds to better well - being .Comparison on Participant Compliance Between Once Daily and Thrice Daily Therapy - Part A [ Time Frame : Weeks 4 up to 28 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "39.882965"}
{"text": "Patients ' peroxidase activity is probably responsible for the other two metabolites which account for 16 % and 4 % of the administered dose , respectively .", "label": "", "metadata": {}, "score": "40.283295"}
{"text": "In these trials , the combination of rosiglitazone 4 mg or 8 mg daily ( administered as single- or twice - daily divided doses ) and a sulfonylurea significantly reduced FPG and HbA1c compared with placebo plus sulfonylurea or further up - titration of the sulfonylurea .", "label": "", "metadata": {}, "score": "40.357834"}
{"text": "Description .Placebo .Each participant received matching placebo once daily for 18 weeks with protocol - specified doses of metformin alone or metformin plus sulphonylurea .", "label": "", "metadata": {}, "score": "41.79279"}
{"text": "A total score ranged from 0 to 160 .A lower value corresponds to better well - being .Comparison of Quality of Life ( QoL ) Assessed by Psychological General Well Being ( PGWB ) Total Scores Between Once Daily and Thrice Daily Therapy-", "label": "", "metadata": {}, "score": "41.860428"}
{"text": "Patients Inadequately Controlled on Diet And Exercise .Patients who received AVANDARYL were randomized to 1 of 2 titration schemes differing in the maximum total daily dose ( 4 mg/4 mg or 8 mg/4 mg ) .", "label": "", "metadata": {}, "score": "42.261425"}
{"text": "Table 8 : Glycemic Parameters in 24- to 26-Week Combination Trials of Rosiglitazone Plus Sulfonylurea .One of the 24- to 26-week trials included patients who were inadequately controlled on maximal doses of glyburide and switched to 4 mg of rosiglitazone daily as monotherapy ; in this group , loss of glycemic control was demonstrated , as evidenced by increases in FPG and HbA1c .", "label": "", "metadata": {}, "score": "42.840576"}
{"text": "Van Heeswijk RPG , Veldkamp AI , Hoetelmans RMW , et al .The steady - state plasma pharmacokinetics of indinavir alone or in combination with ritonavir in twice daily dosing regimens in HIV-1 infected patients .", "label": "", "metadata": {}, "score": "43.155315"}
{"text": "A higher score represents better well - being .Change From Baseline to 12 Weeks in Diurnal Fatigue Questionnaire for Day Average of Once Daily Therapy - Part A [ Time Frame : Baseline ( week 0 ) , Week 12 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "43.47793"}
{"text": "No text entered .Reporting Groups .Description .Placebo .Each participant received matching placebo once daily for 18 weeks with protocol - specified doses of metformin alone or metformin plus sulphonylurea .", "label": "", "metadata": {}, "score": "43.523285"}
{"text": "Official Title : .An Open - Label Study to Evaluate the Multiple Dose Pharmacokinetics of Canagliflozin ( JNJ-28431754 ) and Metformin Following Once - Daily Administration of 2 Canagliflozin / Metformin XR ( 150/1,000-mg )", "label": "", "metadata": {}, "score": "43.966263"}
{"text": "A higher value in the SF-36 questionnaire corresponds to better well - being .Comparison of Quality of Life ( QoL ) Assessed by Fatigue Impact Scale ( FIS ) Total Score Between Once Daily and Thrice Daily Therapy - Part A [ Time Frame : 12 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "44.354286"}
{"text": "Blood glucose and serum C - peptide concentrations were unaffected and no hypoglycemic symptoms were reported .H2-receptor Antagonists : Coadministration of either cimetidine ( 800 mg once daily ) or ranitidine ( 150 mg twice daily ) with a single 4-mg oral dose of glimepiride did not significantly alter the absorption and disposition of glimepiride , and no differences were seen in hypoglycemic symptomatology .", "label": "", "metadata": {}, "score": "44.387047"}
{"text": "All treatments were administered as a once - daily regimen .Improvements in FPG and HbA1c were observed in patients treated with AVANDARYL compared with either rosiglitazone or glimepiride alone ( see Table 7 ) .", "label": "", "metadata": {}, "score": "44.614746"}
{"text": "After multiple oral doses the pharmacokinetics of meloxicam capsules were dose - proportional over the range of 7.5 mg to 15 mg .Mean C max was achieved within four to five hours after a 7.5 mg meloxicam tablet was taken under fasted conditions , indicating a prolonged drug absorption .", "label": "", "metadata": {}, "score": "44.922024"}
{"text": "The clinical relevance of this interaction has not been established .Cimetidine : Concomitant administration of 200 mg cimetidine four times daily did not alter the single - dose pharmacokinetics of 30 mg meloxicam .", "label": "", "metadata": {}, "score": "44.96575"}
{"text": "Combination therapy with rosiglitazone and sulfonylureas improved glycemic control in both males and females with a greater therapeutic response observed in females .For a given body mass index ( BMI ) , females tend to have a greater fat mass than males .", "label": "", "metadata": {}, "score": "45.098114"}
{"text": "No hypoglycemic symptoms were reported .Animal Toxicology And / Or Pharmacology .Rosiglitazone .Heart weights were increased in mice ( 3 mg / kg / day ) , rats ( 5 mg / kg / day ) , and dogs ( 2 mg / kg / day ) with rosiglitazone treatments ( approximately 5 , 22 , and 2 times human AUC at the maximum recommended human daily dose , respectively ) .", "label": "", "metadata": {}, "score": "45.352448"}
{"text": "Achievement of maximal blood pressure response to a given dose in most patients may take 2 to 3 weeks of treatment .Onset of blood pressure reduction is seen within 1 to 2 hours of dosing with few instances of orthostatic hypotension .", "label": "", "metadata": {}, "score": "45.401154"}
{"text": "The efficacy analysis used the ACR Pediatric 30 responder definition , a composite of parent and investigator assessments , counts of active joints and joints with limited range of motion , and erythrocyte sedimentation rate .", "label": "", "metadata": {}, "score": "45.536415"}
{"text": "The titrated and nontitrated groups were pooled for efficacy analysis .In addition , 31 % of the 1 mg per day group and 31 % of the 2 mg per day group were continuously abstinent from one week after TQD through the end of treatment as compared to 8 % of the placebo group .", "label": "", "metadata": {}, "score": "45.54145"}
{"text": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol - specified doses of metformin alone or metformin plus sulphonylurea .Canagliflozin 300 mg .", "label": "", "metadata": {}, "score": "45.54178"}
{"text": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol - specified doses of metformin alone or metformin plus sulphonylurea .Canagliflozin 300 mg .", "label": "", "metadata": {}, "score": "45.54178"}
{"text": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol - specified doses of metformin alone or metformin plus sulphonylurea .Canagliflozin 300 mg .", "label": "", "metadata": {}, "score": "45.54178"}
{"text": "For 44 % of patients , the modal dose selected was 1 mg twice daily ; for slightly over half of the study participants , the modal dose selected was 1 mg / day or less .", "label": "", "metadata": {}, "score": "45.577385"}
{"text": "However , if beta - blockers are used , caution should be exercised and patients should be warned about the potential for hypoglycemia .Warfarin : Concomitant administration of glimepiride tablets ( 4 mg once daily ) did not alter the pharmacokinetic characteristics of R- and S - warfarin enantiomers following administration of a single dose ( 25 mg ) of racemic warfarin to healthy subjects .", "label": "", "metadata": {}, "score": "45.777817"}
{"text": "In all studies , patients were provided with an educational booklet on smoking cessation and received up to 10 minutes of smoking cessation counseling at each weekly treatment visit according to Agency for Healthcare Research and Quality guidelines .", "label": "", "metadata": {}, "score": "45.783833"}
{"text": "Pharmacokinetics .Absorption / Distribution .Maximum plasma concentrations of varenicline occur typically within 3 - 4 hours after oral administration .Following administration of multiple oral doses of varenicline , steady - state conditions were reached within 4 days .", "label": "", "metadata": {}, "score": "46.140995"}
{"text": "Trials with single oral doses in normal subjects and with multiple oral doses in patients with type 2 diabetes have shown significant absorption of glimepiride within 1 hour after administration and Cmax at 2 to 3 hours .", "label": "", "metadata": {}, "score": "46.16143"}
{"text": "Aarnoutse R , Burger D , van Oosterhout J , et al .Multiple dose pharmacokinetics ( PK ) and tolerability of once daily ( OD ) nelfinavir ( NFV ) and ritonavir combinations in healthy volunteers [ abstract # 1.3]. 2nd", "label": "", "metadata": {}, "score": "46.28667"}
{"text": "In particular , the risk of hypoglycemia and weight gain with dual therapy should be taken into account .[See WARNINGS AND PRECAUTIONS , ADVERSE REACTIONS ] .", "label": "", "metadata": {}, "score": "46.63053"}
{"text": "These identical double - blind studies compared CHANTIX 2 mg per day , bupropion sustained - release ( SR ) 150 mg twice daily , and placebo .", "label": "", "metadata": {}, "score": "46.630764"}
{"text": "Saah A , Winchell G , Seniuk M , et al .Multiple - dose pharmacokinetics and tolerability of indinavir and ritonavir combinations in a once - daily regimen in healthy volunteers ( Merck 089 ) [ abstract # 329].", "label": "", "metadata": {}, "score": "46.639664"}
{"text": "The reference drug was administered orally thrice daily ( at 8 AM , 12 AM and 4 PM)in the same total daily dose as the experimental drug .", "label": "", "metadata": {}, "score": "46.64378"}
{"text": "1998;12(suppl 4):S31 .van Heeswijk , Veldkamp AI , Hoetelmans RMW , et al .The steady - state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regiments in HIV-1 infected individuals .", "label": "", "metadata": {}, "score": "46.855217"}
{"text": "Peak plasma concentrations are observed about 1 hour after dosing .The Cmax and AUC of rosiglitazone increase in a dose - proportional manner over the therapeutic dose range .", "label": "", "metadata": {}, "score": "46.89672"}
{"text": "Official Title : .A , Randomised , Controlled , Two - armed , Two - period Cross - over , Multi - centre Phase II / III Study to Assess the Safety and Pharmacokinetics of Once - daily Oral Modified - release Hydrocortisone in Patients With Adrenal Insufficiency .", "label": "", "metadata": {}, "score": "46.91951"}
{"text": "Glyburide : Rosiglitazone ( 2 mg twice daily ) taken concomitantly with glyburide ( 3.75 to 10 mg / day ) for 7 days did not alter the mean steady - state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy .", "label": "", "metadata": {}, "score": "46.962105"}
{"text": "It does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation .Pharmacokinetics .Absolute bioavailability following a single 300 mg oral dose of eprosartan is approximately 13 % .", "label": "", "metadata": {}, "score": "47.30728"}
{"text": "This flexible - dosing study of 312 patients examined the effect of a patient - directed dosing strategy of CHANTIX or placebo .After an initial oneweek titration to a dose of 0.5 mg twice daily , patients could adjust their dosage as often as they wished between 0.5 mg once daily to 1 mg twice daily per day .", "label": "", "metadata": {}, "score": "47.342834"}
{"text": "One patient was withdrawn from clinical trials for hyperkalemia and three for hypokalemia .Overdosage .Limited data are available regarding overdosage .Appropriate symptomatic and supportive therapy should be given if overdosage should occur .", "label": "", "metadata": {}, "score": "47.419746"}
{"text": "Table 3 Single Dose and Steady - State Pharmacokinetic Parameters for Oral 7.5 mg and 15 mg Meloxicam ( Mean and % CV ) 1 . 15 mg capsules .", "label": "", "metadata": {}, "score": "47.466743"}
{"text": "t1/2[5 - 24h ] is the time taken for the blood plasma concentration of a drug to halve from 5 to 24 hours .The average of single and multiple dosing for combined arm 1 + 2 was reported .", "label": "", "metadata": {}, "score": "47.7801"}
{"text": "The results were consistent with those observed after single doses .All patients with a CLcr less than 22 mL / min had adequate control of their glucose levels with a dosage regimen of only 1 mg daily .", "label": "", "metadata": {}, "score": "47.859608"}
{"text": "This was demonstrated when oral administration of cholestyramine following a single IV dose of meloxicam decreased the AUC of meloxicam by 50 % .The mean elimination half - life ( t 1/2 ) ranges from 15 hours to 20 hours .", "label": "", "metadata": {}, "score": "48.142788"}
{"text": "Pharmacodynamics .The lipid profiles of rosiglitazone and glimepiride in a clinical trial of patients with inadequate glycemic control on diet and exercise were consistent with the known profile of each monotherapy .", "label": "", "metadata": {}, "score": "48.365143"}
{"text": "Closely observe infants with histories of in utero exposure to Teveten for hypotension , oliguria , and hyperkalemia ( see PRECAUTIONS , Pediatric Use ) .", "label": "", "metadata": {}, "score": "48.76889"}
{"text": "Drug - drug Interactions .Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady - state pharmacokinetics of rosiglitazone .", "label": "", "metadata": {}, "score": "48.913937"}
{"text": "The average total score ranges from 1 to 5 with a higher score representing better tolerability of the treatment .Percentage ( % ) of Participants With Change From Baseline in Patient Tolerability Questionnaire at Month 6 , Assessed by Patient and Investigator - Part B [ Time Frame : Baseline ( week 0 ) , month 6 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "49.130157"}
{"text": "The recovery of M1 and M2 from urine , however , did not change .The pharmacodynamic responses to glimepiride were nearly identical in normal subjects receiving propranolol and placebo .", "label": "", "metadata": {}, "score": "49.5381"}
{"text": "This study of 627 patients compared CHANTIX 1 mg per day and 2 mg per day with placebo .Patients were treated for 12 weeks ( including one week titration ) and then were followed for 40 weeks post - treatment .", "label": "", "metadata": {}, "score": "49.63173"}
{"text": "PRECAUTIONS .Risk of Renal Impairment .As a consequence of inhibiting the renin - angiotensin - aldosterone system , changes in renal function have been reported in susceptible individuals treated with angiotensin II antagonists ; in some patients , these changes in renal function were reversible upon discontinuation of therapy .", "label": "", "metadata": {}, "score": "49.746952"}
{"text": "Non - Steroidal Anti - Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors ( COX-2 Inhibitors ) .These effects are usually reversible .Monitor renal function periodically in patients receiving eprosartan and NSAID therapy .", "label": "", "metadata": {}, "score": "49.785645"}
{"text": "The table below shows the least - squares ( LS ) mean change in HbA1c from baseline to Week 18 for each treatment group .The statistical analyses show the treatment differences ( ie , each canagliflozin group minus placebo ) in the LS mean change .", "label": "", "metadata": {}, "score": "49.80088"}
{"text": "Reporting Groups .Description .Nintedanib 150 mg + Afatinib 30 mg - Continuously .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 150 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 30 mg was given continuously once daily ( q.d . ) .", "label": "", "metadata": {}, "score": "49.887894"}
{"text": "A greater than 20 % decrease in hemoglobin was observed in 0.1 % of patients taking Teveten \u00ae ( one patient ) and in no patient given placebo in controlled clinical trials .", "label": "", "metadata": {}, "score": "50.067146"}
{"text": "In Japanese subjects , glyburide AUC and Cmax slightly increased following coadministration of rosiglitazone .Digoxin : Repeat oral dosing of rosiglitazone ( 8 mg once daily ) for 14 days did not alter the steady - state pharmacokinetics of digoxin ( 0.375 mg once daily ) in healthy volunteers .", "label": "", "metadata": {}, "score": "50.432602"}
{"text": "Hsu A , Granneman GR , Witt G , et al .Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline [ abstract # 1200].", "label": "", "metadata": {}, "score": "50.501915"}
{"text": "Objective Response ( OR )During the Expansion Phase [ Time Frame : Tumour assessment was to be performed at Screening , every 6 weeks after starting study treatment until disease progression , and at the end - of - treatment ( EOT ) visit ( up to 1117 days ) ] .", "label": "", "metadata": {}, "score": "50.60216"}
{"text": "About 78 % of the patients on combination therapy completed the 2 years of therapy while only 51 % completed on glipizide monotherapy .The effect of combination therapy on FPG and HbA1c was durable over the 2-year trial period , with patients achieving a mean of 132 mg / dL for FPG and a mean of 6.98 % for HbA1c compared with no change on the glipizide arm .", "label": "", "metadata": {}, "score": "50.61225"}
{"text": "The average of single and multiple dosing for combined arm 1 + 2 was reported .AUC can be used as a measure of drug exposure .", "label": "", "metadata": {}, "score": "50.66616"}
{"text": "The average of single and multiple dosing for combined arm 1 + 2 was reported .AUC can be used as a measure of drug exposure .", "label": "", "metadata": {}, "score": "50.66616"}
{"text": "The average of single and multiple dosing for combined arm 1 + 2 was reported .AUC can be used as a measure of drug exposure .", "label": "", "metadata": {}, "score": "50.66616"}
{"text": "The average of single and multiple dosing for combined arm 1 + 2 was reported .AUC can be used as a measure of drug exposure .", "label": "", "metadata": {}, "score": "50.66616"}
{"text": "The average of single and multiple dosing for combined arm 1 + 2 was reported .AUC can be used as a measure of drug exposure .", "label": "", "metadata": {}, "score": "50.66616"}
{"text": "Each patient will receive 2 tablets of CANA / MET XR combination of total dose 300/2000 mg .Drug : CANA / MET XR FDC .", "label": "", "metadata": {}, "score": "50.729042"}
{"text": "A combined single- and multiple - dose pharmacokinetic study demonstrated that the pharmacokinetics of 1 mg varenicline given once daily or twice daily to 16 healthy elderly male and female smokers ( aged 65 - 75 yrs ) for 7 consecutive days was similar to that of younger subjects .", "label": "", "metadata": {}, "score": "50.83007"}
{"text": "Plasma clearance ranges from 7 to 9 mL / min .Special Populations .The older patients had meloxicam exposures similar ( single dose ) or slightly reduced ( steady state ) to those in the adult patients , when using AUC values normalized to a dose of 0.25 mg / kg [ . see Dosage and Administration ] .", "label": "", "metadata": {}, "score": "50.92085"}
{"text": "In Figure 3 below , the x- axis represents the study week for each observation , allowing a comparison of groups at similar times after discontinuation of CHANTIX ; post - CHANTIX follow - up begins at Week 13 for the placebo group and Week 25 for the CHANTIX group .", "label": "", "metadata": {}, "score": "51.1643"}
{"text": "The pattern of LDL and HDL changes following therapy with rosiglitazone in patients previously treated with a sulfonylurea was generally similar to those seen with rosiglitazone in monotherapy .", "label": "", "metadata": {}, "score": "51.196877"}
{"text": "The plasma half - life of [ 14 C]related material ranged from 103 to 158 hours .The elimination half - life is 3 to 4 hours and is independent of dose .", "label": "", "metadata": {}, "score": "51.28836"}
{"text": "Measured Values .Placebo .Change in Glycosylated Hemoglobin ( HbA1c )From Baseline to Week 18 [ units : Percent ] Least Squares Mean ( Standard Error ) .", "label": "", "metadata": {}, "score": "51.293083"}
{"text": "A second meloxicam concentration peak occurs around 12 to 14 hours post - dose suggesting biliary recycling .Meloxicam oral suspension doses of 7.5 mg/5 mL and 15 mg/10 mL have been found to be bioequivalent to meloxicam 7.5 mg and 15 mg capsules , respectively .", "label": "", "metadata": {}, "score": "51.305214"}
{"text": "In general , avoid combined use of RAS inhibitors .Closely monitor blood pressure , renal function and electrolytes in patients on Teveten and other agents that affect the RAS .", "label": "", "metadata": {}, "score": "51.66417"}
{"text": "Abstract 2.6 .Penzak S , Formentini E , Alfaro R , et al .Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers .", "label": "", "metadata": {}, "score": "51.74241"}
{"text": "If hypotension occurs , the patient should be placed in the supine position and , if necessary , given an intravenous infusion of normal saline .", "label": "", "metadata": {}, "score": "51.82927"}
{"text": "Plasma concentrations of eprosartan increase in a slightly less than dose - proportional manner over the 100 mg to 800 mg dose range .The mean terminal elimination half - life of eprosartan following multiple oral doses of 600 mg was approximately 20 hours .", "label": "", "metadata": {}, "score": "51.97177"}
{"text": "Boyd S , Hadigan C , Pau A , et al .Darunavir / ritonavir does not significantly increase plasma concentrations of orally inhaled beclomethasone in healthy volunteers [ paper # 611]. 19th", "label": "", "metadata": {}, "score": "52.058613"}
{"text": "Warnings .Fetal Toxicity .Pregnancy Category D .Use of drugs that act on the renin - angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death .", "label": "", "metadata": {}, "score": "52.068085"}
{"text": "The average of single and multiple dosing for combined arm 1 + 2 was reported .The average of single and multiple dosing for combined arm 1 + 2 was reported .", "label": "", "metadata": {}, "score": "52.09306"}
{"text": "The average of single and multiple dosing for combined arm 1 + 2 was reported .The average of single and multiple dosing for combined arm 1 + 2 was reported .", "label": "", "metadata": {}, "score": "52.09306"}
{"text": "The average of single and multiple dosing for combined arm 1 + 2 was reported .The average of single and multiple dosing for combined arm 1 + 2 was reported .", "label": "", "metadata": {}, "score": "52.09306"}
{"text": "The total daily dose was the same as in the experimental treatment arm .Detailed Description : .Adrenal insufficiency is a disease with more than 80 % 1-year mortality before the availability of synthetic glucocorticoids .", "label": "", "metadata": {}, "score": "52.097317"}
{"text": "Special Populations .The extent of plasma protein binding was not influenced by age .Following administration of 600 mg once daily , there was a 70 - 90 % increase in AUC , and a 30 - 50 % increase in C max in moderate or severe renal impairment .", "label": "", "metadata": {}, "score": "52.1533"}
{"text": "Change From Baseline to 6 Months in Quality of Life ( QoL ) Assessed by Psychological General Well Being ( PGWB ) Total Scores-Part B [ Time Frame : Baseline ( week 0 ) , month 6 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "52.25756"}
{"text": "Studies 1 through 5 included 40 weeks of post - treatment follow - up .In each study , CHANTIX - treated patients were more likely to maintain abstinence throughout the follow - up period than were patients treated with placebo ( Figure 2 , Table 7 ) .", "label": "", "metadata": {}, "score": "52.30062"}
{"text": "For treatment of gout , reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later .Dose not to be repeated no earlier than 3 days .", "label": "", "metadata": {}, "score": "52.424248"}
{"text": "Comparison of Quality of Life ( QoL ) Assessed by Short Form-36 Survey ( SF-36 )For Physical and Mental Component Score Between Once Daily and Thrice Daily Therapy-", "label": "", "metadata": {}, "score": "52.505676"}
{"text": "The use of MOBIC for the management of signs and symptoms of osteoarthritis was evaluated in six double - blind , active - controlled trials outside the U.S. ranging from 4 weeks ' to 6 months ' duration .", "label": "", "metadata": {}, "score": "52.52976"}
{"text": "Kurowski M , Arslan A , Moecklinghoff C , Hill A. Comparative pharmacokinetics of twice daily ( BID ) Fortovase / ritonavir and Invirase / ritonavir [ abstract # 3.2]. 2nd", "label": "", "metadata": {}, "score": "52.556732"}
{"text": "Krishna G , Moton A , Ma L , et al .Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers .", "label": "", "metadata": {}, "score": "52.583466"}
{"text": "At study endpoint , patients treated with Teveten \u00ae at doses of 600 mg to 1200 mg given once daily experienced significant decreases in sitting systolic and diastolic blood pressure at trough , with differences from placebo of approximately 5 - 10/3 - 6 mmHg .", "label": "", "metadata": {}, "score": "52.616066"}
{"text": "Young females exhibited slightly lower plasma concentrations relative to young males .After single doses of 7.5 mg MOBIC , the mean elimination half - life was 19.5 hours for the female group as compared to 23.4 hours for the male group .", "label": "", "metadata": {}, "score": "53.08567"}
{"text": "The average of single and multiple dosing for combined arm 1 + 2 was reported .Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached .", "label": "", "metadata": {}, "score": "53.113743"}
{"text": "The average of single and multiple dosing for combined arm 1 + 2 was reported .Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached .", "label": "", "metadata": {}, "score": "53.113743"}
{"text": "Absorption .The AUC and Cmax of glimepiride increased in a dose - proportional manner following administration of AVANDARYL 4 mg/1 mg , 4 mg/2 mg , and 4 mg/4 mg .", "label": "", "metadata": {}, "score": "53.248314"}
{"text": "Cato A , Qian J , Hsu A , et al .Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV - infected patients .", "label": "", "metadata": {}, "score": "53.34932"}
{"text": "Peak ( 1 to 3 hours ) effects were uniformly , but moderately , larger than trough effects with b.i.d . dosing , with the trough - to - peak ratio for diastolic blood pressure 65 % to 80 % .", "label": "", "metadata": {}, "score": "53.35085"}
{"text": "Patient receiving replacement therapy with hydrocortisone or cortisone acetate have compromised quality of life , reduced bone mass , increased risk factors for cardiovascular disease and premature mortality that is more than twice the mortality rate in the background population .", "label": "", "metadata": {}, "score": "53.397873"}
{"text": "No incremental benefit was observed with the 22.5 mg dose compared to the 15 mg dose .Juvenile RheumatoidArthritis ( JRA ) Pauciarticular and Polyarticular Course .", "label": "", "metadata": {}, "score": "53.45102"}
{"text": "In a covariate analysis , utilizing population pharmacokinetics body - weight , but not age , was the single predictive covariate for differences in the meloxicam apparent oral plasma clearance .", "label": "", "metadata": {}, "score": "53.58185"}
{"text": "Elderly , Hepatically Impaired or Renally Impaired Patients .No initial dosing adjustment is generally necessary for elderly or hepatically impaired patients or those with renal impairment .", "label": "", "metadata": {}, "score": "53.641357"}
{"text": "Using available formulations for replacement therapy this circadian rhythm is had to mimic and also during the active time of the day high peaks and low troughs occur .", "label": "", "metadata": {}, "score": "53.898605"}
{"text": "Burger DM , Hugen PWH , Prins JM , et al .Pharmacokinetics of an indinavir / ritonavir 800/100 mg bid regimen [ abstract # 363].", "label": "", "metadata": {}, "score": "53.93352"}
{"text": "Saah AJ , Winchell G , Seniuk M , et al .Multiple - dose pharmacokinetics and tolerability of indinavir ritonavir combinations in healthy volunteers [ abstract # 362].", "label": "", "metadata": {}, "score": "53.962654"}
{"text": "In a direct comparison of 200 mg to 400 mg b.i.d .with 400 mg to 800 mg q.d . of Teveten \u00ae , effects at trough were similar .", "label": "", "metadata": {}, "score": "54.229904"}
{"text": "The population mean steady - state volume of distribution ( Vss / F ) was 308 L. Eprosartan pharmacokinetics were not influenced by weight , race , gender or severity of hypertension at baseline .", "label": "", "metadata": {}, "score": "54.263084"}
{"text": "Adverse experiences were not dose - related .In placebo - controlled clinical trials , about 4 % of 1,202 patients treated with Teveten \u00ae discontinued therapy due to clinical adverse experiences , compared to 6.5 % of 352 patients given placebo .", "label": "", "metadata": {}, "score": "54.26763"}
{"text": "Varenicline ( 1 mg twice daily ) did not alter the pharmacokinetics of a single 25 mg dose of ( R , S)-warfarin in 24 smokers .", "label": "", "metadata": {}, "score": "54.31402"}
{"text": "Renal Impairment .In subjects with end - stage - renal disease ( ESRD ) undergoing a three - hour session of hemodialysis for three days a week , varenicline exposure was increased 2.7-fold following 0.5 mg once daily administration for 12 days .", "label": "", "metadata": {}, "score": "54.36516"}
{"text": "The average of single and multiple dosing for combined arm 1 + 2 was reported .It was peak trough fluctuation within one dosing interval at steady state .", "label": "", "metadata": {}, "score": "54.40544"}
{"text": "Clinical Trials .There is also some experience with use of eprosartan together with other anti - hypertensive drugs in more severe hypertension .The five studies included 1,111 patients randomized to eprosartan and 395 patients randomized to placebo .", "label": "", "metadata": {}, "score": "54.40602"}
{"text": "Part B [ Time Frame : Up to Month 6 follow - up ] [ Designated as safety issue : No ] .Comparison on Participant Preference by Questionnaire Between Once Daily and Thrice Daily Therapy - Part A [ Time Frame : Weeks 16 up to 28 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "54.432396"}
{"text": "Subjects will receive orally 25 mg TMC207 po q.d .( Treatment A ) , 100 mg TMC207 po q.d .( Treatment B ) or 400 mg TMC207 po q.d .", "label": "", "metadata": {}, "score": "54.489304"}
{"text": "Pediatric : No pharmacokinetic data from trials in pediatric subjects are available for AVANDARYL .Population mean CL / F and V / F of rosiglitazone were 3.15 L / h and 13.5 L , respectively .", "label": "", "metadata": {}, "score": "54.514694"}
{"text": "The pharmacokinetics of MOBIC in pediatric patients under 2 years of age have not been investigated .Despite the increased total concentrations in the elderly females , the adverse event profile was comparable for both elderly patient populations .", "label": "", "metadata": {}, "score": "54.520996"}
{"text": "[See DRUG INTERACTIONS ] .Rosiglitazone ( 4 mg twice daily ) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives ( ethinyl estradiol and norethindrone ) , which are predominantly metabolized by CYP3A4 .", "label": "", "metadata": {}, "score": "54.572823"}
{"text": "This study assessed the effect of an additional 12 weeks of CHANTIX therapy on the likelihood of long - term abstinence .The continuous abstinence rate from Week 13 through Week 24 was higher for patients continuing treatment with CHANTIX ( 70 % ) than for patients switching to placebo ( 50 % ) .", "label": "", "metadata": {}, "score": "54.59933"}
{"text": "Adverse experiences were similar in younger and older patients .Adverse Reactions .Teveten \u00ae has been evaluated for safety in more than 3,300 healthy volunteers and patients worldwide , including more than 1,460 patients treated for more than 6 months , and more than 980 patients treated for 1 year or longer .", "label": "", "metadata": {}, "score": "54.68803"}
{"text": "15 mg capsules .15 mg capsules .N .Food and AntacidEffects .Administration of meloxicam capsules following a high fat breakfast ( 75 g of fat ) resulted in mean peak drug levels ( i.e. , C max ) being increased by approximately 22 % while the extent of absorption ( AUC ) was unchanged .", "label": "", "metadata": {}, "score": "54.8451"}
{"text": "It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body .The data for combined arm 1 + 2 after multiple doses were reported .", "label": "", "metadata": {}, "score": "55.012188"}
{"text": "Pharmacodynamics .Pharmacokinetics .Absorption .The absolute bioavailability of meloxicam capsules was 89 % following a single oral dose of 30 mg compared with 30 mg IV bolus injection .", "label": "", "metadata": {}, "score": "55.078114"}
{"text": "Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin - angiotensin system from other antihypertensive agents .", "label": "", "metadata": {}, "score": "55.118034"}
{"text": "No initial dosing adjustment is generally necessary in patients with moderate or severe renal impairment , with maximum dose not exceeding 600 mg daily .Eprosartan AUC ( but not C max ) values increased , on average , by approximately 40 % in men with decreased hepatic function compared to healthy men after a single 100 mg oral dose of eprosartan .", "label": "", "metadata": {}, "score": "55.21496"}
{"text": "Glimepiride was found to be well tolerated in all 3 groups .The results showed that glimepiride serum levels decreased as renal function decreased .However , M1 and M2 serum levels ( mean AUC values ) increased 2.3 and 8.6 times from Group I to Group III .", "label": "", "metadata": {}, "score": "55.307823"}
{"text": "The changes in triglycerides during therapy with rosiglitazone were variable and were generally not statistically different from placebo or glyburide controls .Pharmacokinetics .In a bioequivalence trial of AVANDARYL 4 mg/4 mg , the area under the curve ( AUC ) and maximum concentration ( Cmax ) of rosiglitazone following a single dose of the combination tablet were bioequivalent to rosiglitazone 4 mg concomitantly administered with glimepiride 4 mg under fasted conditions .", "label": "", "metadata": {}, "score": "55.81685"}
{"text": "This is supported by both preclinical and clinical trials demonstrating that glimepiride administration can lead to increased sensitivity of peripheral tissues to insulin .These findings are consistent with the results of a long - term , randomized , placebo - controlled trial in which glimepiride therapy improved postprandial insulin/ C - peptide responses and overall glycemic control without producing clinically meaningful increases in fasting insulin / C- peptide levels .", "label": "", "metadata": {}, "score": "55.977184"}
{"text": "Here , \" N\"signifies the number of participants evaluable for this outcome .AUC can be used as a measure of drug exposure .It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body .", "label": "", "metadata": {}, "score": "56.152596"}
{"text": "In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin - angiotensin system for a particular patient , apprise the mother of the potential risk to the fetus .", "label": "", "metadata": {}, "score": "56.224884"}
{"text": "Sadler BM , Piliero PJ , Preston SL , et al .Pharmacokinetic ( PK ) drug - interaction between amprenavir ( APV ) and ritonavir ( RTV ) in HIV - seronegative subjects after multiple , oral dosing [ abstract # 77].", "label": "", "metadata": {}, "score": "56.23855"}
{"text": "Fiske W , Benedek IH , et al .Pharmacokinetics of efavirenz ( EFV ) and ritonavir ( RIT ) after multiple oral doses in healthy volunteers [ abstract # 42269].", "label": "", "metadata": {}, "score": "56.43454"}
{"text": "When these drugs are withdrawn from a patient receiving glimepiride , the patient should be observed closely for loss of glycemic control .Certain drugs tend to produce hyperglycemia and may lead to loss of control .", "label": "", "metadata": {}, "score": "56.510937"}
{"text": "Change From Baseline to 6 Months in Diurnal Fatigue Questionnaire for Day Average- Part B [ Time Frame : Baseline ( week 0 ) , month 6 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "56.515816"}
{"text": "In total , 678 participants were randomly allocated to the 3 treatment arms , 676 received at least 1 dose of study drug and were included in the modified intent - to - treat ( mITT ) analysis set and the safety analysis set .", "label": "", "metadata": {}, "score": "56.538"}
{"text": "The average of single and multiple dosing for combined arm 1 + 2 was reported .Css , av was calculated as the area under the S - cortisol concentration versus time curve during a dosing interval at steady state ( AUCtau ) divided by dosing interval ( tau ) .", "label": "", "metadata": {}, "score": "56.60164"}
{"text": "In addition , 29 % of the CHANTIX group were continuously abstinent from one week after TQD through the end of treatment as compared to 9 % of the placebo group .", "label": "", "metadata": {}, "score": "56.8544"}
{"text": "Aspirin : When MOBIC is administered with aspirin ( 1000 mg three times daily ) to healthy volunteers , it tended to increase the AUC ( 10 % ) and C max ( 24 % ) of meloxicam .", "label": "", "metadata": {}, "score": "57.034092"}
{"text": "Drug Interactions .Dual blockade of the RAS with angiotensin receptor blockers , ACE inhibitors , or aliskiren is associated with increased risks of hypotension , hyperkalemia , and changes in renal function ( including acute renal failure ) compared to monotherapy .", "label": "", "metadata": {}, "score": "57.036377"}
{"text": "Antimicrob Agents Chemother 2000;44:2672 - 8 .Wire MB , Preston SL , Ballow C , et al .An assessment of plasma amprenavir pharmacokinetics following administration of two GW433908 and ritonavir QD regimens in combination with efavirenz in healthy adult subjects ( APV10009 ) [ abstract # 1737]. 41st", "label": "", "metadata": {}, "score": "57.09603"}
{"text": "After IV dosing in patients , no significant biliary excretion of glimepiride or its M1 metabolite has been observed .Special Populations .No pharmacokinetic data are available for AVANDARYL in the following special populations .", "label": "", "metadata": {}, "score": "57.11268"}
{"text": "The safety and efficacy of rosiglitazone added to a sulfonylurea have been studied in clinical trials in patients with type 2 diabetes inadequately controlled on sulfonylureas alone .", "label": "", "metadata": {}, "score": "57.135994"}
{"text": "A total of 3,457 patients with type 2 diabetes participated in ten 24- to 26-week randomized , double - blind , placebo / active - controlled trials and one 2-year double - blind , activecontrolled trial in elderly patients designed to assess the efficacy and safety of rosiglitazone in combination with a sulfonylurea .", "label": "", "metadata": {}, "score": "57.225704"}
{"text": "In one study , patients who had previously coughed while taking an ACE inhibitor were treated with eprosartan , an ACE inhibitor ( enalapril ) or placebo for six weeks .", "label": "", "metadata": {}, "score": "57.27921"}
{"text": "Neonates with a history of in utero exposure to Teveten : .If oliguria or hypotension occurs , direct attention toward support of blood pressure and renal perfusion .", "label": "", "metadata": {}, "score": "57.311058"}
{"text": "The purpose of this study is to assess the effects of 3 different oral doses of TMC207 administered over a 7 day period on the organism that causes tuberculosis .", "label": "", "metadata": {}, "score": "57.332817"}
{"text": "The use of MOBIC for the treatment of the signs and symptoms of rheumatoid arthritis was evaluated in a 12-week , double - blind , controlled multinational trial .", "label": "", "metadata": {}, "score": "57.485653"}
{"text": "In animal models , the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulin 's action in the liver , muscle , and adipose tissues .", "label": "", "metadata": {}, "score": "57.53184"}
{"text": "Nintedanib 200 mg + Afatinib 30 mg - Intermittently .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 200 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 30 mg was given intermittently once daily ( q.d . ) every other week .", "label": "", "metadata": {}, "score": "57.567825"}
{"text": "Nintedanib 200 mg + Afatinib 30 mg - Intermittently .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 200 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 30 mg was given intermittently once daily ( q.d . ) every other week .", "label": "", "metadata": {}, "score": "57.567825"}
{"text": "This pharmacokinetic difference due to gender is likely to be of little clinical importance .There was linearity of pharmacokinetics and no appreciable difference in the C max or T max across genders .", "label": "", "metadata": {}, "score": "57.6429"}
{"text": "Elimination half - life for rosiglitazone was about 2 hours longer in patients with liver disease , compared with healthy subjects .Glimepiride : No trials of glimepiride have been conducted in patients with hepatic insufficiency .", "label": "", "metadata": {}, "score": "57.661102"}
{"text": "Significant events and approaches for the overall study following participant enrollment , but prior to group assignment .No text entered .Reporting Groups .Description .", "label": "", "metadata": {}, "score": "57.859085"}
{"text": "In hypertensive patients treated chronically with eprosartan , there was a twofold rise in angiotensin II plasma concentration and a twofold rise in plasma renin activity , while plasma aldosterone levels remained unchanged .", "label": "", "metadata": {}, "score": "57.945312"}
{"text": "Nintedanib 150 mg + Afatinib 40 mg - Intermittently .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 150 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 40 mg was given intermittently once daily ( q.d . ) every other week .", "label": "", "metadata": {}, "score": "58.01819"}
{"text": "Nintedanib 150 mg + Afatinib 40 mg - Intermittently .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 150 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 40 mg was given intermittently once daily ( q.d . ) every other week .", "label": "", "metadata": {}, "score": "58.01819"}
{"text": "Nintedanib 200 mg + Afatinib 40 mg - Intermittently .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 200 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 40 mg was given intermittently once daily ( q.d . ) every other week .", "label": "", "metadata": {}, "score": "58.025017"}
{"text": "Nintedanib 200 mg + Afatinib 40 mg - Intermittently .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 200 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 40 mg was given intermittently once daily ( q.d . ) every other week .", "label": "", "metadata": {}, "score": "58.025017"}
{"text": "Study 1 .This was a six - week dose - ranging study comparing CHANTIX to placebo .This study provided initial evidence that CHANTIX at a total dose of 1 mg per day or 2 mg per day was effective as an aid to smoking cessation .", "label": "", "metadata": {}, "score": "58.06031"}
{"text": "Eprosartan did not reduce glomerular filtration rate in patients with renal insufficiency or in patients with hypertension , after 7 days and 28 days of dosing , respectively .", "label": "", "metadata": {}, "score": "58.091385"}
{"text": "Nintedanib 200 mg + Afatinib 10 mg - Continuously .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 200 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 10 mg was given continuously once daily ( q.d . ) .", "label": "", "metadata": {}, "score": "58.122498"}
{"text": "Nintedanib 200 mg + Afatinib 10 mg - Continuously .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 200 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 10 mg was given continuously once daily ( q.d . ) .", "label": "", "metadata": {}, "score": "58.122498"}
{"text": "Additional pharmacokinetic trials demonstrated no clinically relevant effect of acarbose , ranitidine , or metformin on the pharmacokinetics of rosiglitazone .Glimepiride .The hypoglycemic action of sulfonylureas may be potentiated by certain drugs , including nonsteroidal anti - inflammatory drugs ( NSAIDs ) and other drugs that are highly protein bound , such as salicylates , sulfonamides , chloramphenicol , coumarins , probenecid , monoamine oxidase inhibitors , and beta - adrenergic blocking agents .", "label": "", "metadata": {}, "score": "58.221222"}
{"text": "Minor elevations of ALAT , ASAT , and alkaline phosphatase occurred for comparable percentages of patients taking Teveten \u00ae or placebo in controlled clinical trials .", "label": "", "metadata": {}, "score": "58.227173"}
{"text": "Teveten Dosage and Administration .The usual recommended starting dose of Teveten \u00ae is 600 mg once daily when used as monotherapy in patients who are not volume - depleted ( see WARNINGS , Hypotension in Volume- and/or Salt - Depleted Patients ) .", "label": "", "metadata": {}, "score": "58.406326"}
{"text": "Seattle , WA .Avandaryl .CLINICAL PHARMACOLOGY .Mechanism Of Action .AVANDARYL combines 2 antidiabetic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes : Rosiglitazone maleate , a member of the thiazolidinedione class , and glimepiride , a member of the sulfonylurea class .", "label": "", "metadata": {}, "score": "58.568924"}
{"text": "Such review will be done with regard to proprietary information , information related to patentable inventions , medical , scientific , and statistical accuracy within 60 days .", "label": "", "metadata": {}, "score": "58.656677"}
{"text": "Ranitidine also has no effect on eprosartan pharmacokinetics .Eprosartan ( up to 400 mg b.i.d . or 800 mg q.d . ) doses have been safely used concomitantly with a thiazide diuretic ( hydrochlorothiazide ) .", "label": "", "metadata": {}, "score": "58.695488"}
{"text": "Nintedanib 200 mg + Afatinib 20 mg - Continuously .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 200 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 20 mg was given continuously once daily ( q.d . ) .", "label": "", "metadata": {}, "score": "58.88317"}
{"text": "Nintedanib 200 mg + Afatinib 20 mg - Continuously .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 200 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 20 mg was given continuously once daily ( q.d . ) .", "label": "", "metadata": {}, "score": "58.88317"}
{"text": "Nintedanib 200 mg + Afatinib 30 mg - Continuously .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 200 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 30 mg was given continuously once daily ( q.d . ) .", "label": "", "metadata": {}, "score": "58.9506"}
{"text": "Nintedanib 200 mg + Afatinib 30 mg - Continuously .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 200 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 30 mg was given continuously once daily ( q.d . ) .", "label": "", "metadata": {}, "score": "58.9506"}
{"text": "Female patients of childbearing age should be told about the consequences of exposure to Teveten during pregnancy .Discuss treatment options with women planning to become pregnant .", "label": "", "metadata": {}, "score": "58.955856"}
{"text": "Metformin .When co - administered to 30 smokers , varenicline ( 1 mg twice daily ) did not alter the steady - state pharmacokinetics of metformin ( 500 mg twice daily ) , which is a substrate of OCT2 .", "label": "", "metadata": {}, "score": "58.978256"}
{"text": "Safety and effectiveness in pediatric patients have not been established .Geriatric Use .Of the total number of patients receiving Teveten \u00ae in clinical studies , 29 % ( 681 of 2,334 ) were 65 years and over , while 5 % ( 124 of 2,334 ) were 75 years and over .", "label": "", "metadata": {}, "score": "58.987083"}
{"text": "In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis , increases in serum creatinine or BUN have been reported .Similar effects have been reported with angiotensin II antagonists ; in some patients , these effects were reversible upon discontinuation of therapy .", "label": "", "metadata": {}, "score": "59.0863"}
{"text": "Mean urinary excretion of M1 plus M2 as percent of dose , however , decreased ( 44.4 % , 21.9 % , and 9.3 % for Groups I to III ) .", "label": "", "metadata": {}, "score": "59.14134"}
{"text": "Given the potential for dose - related adverse events with rosiglitazone , a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [ see DRUG INTERACTIONS ] .", "label": "", "metadata": {}, "score": "59.20649"}
{"text": "Eprosartan mesylate was not carcinogenic in dietary restricted rats or ad libitum fed mice dosed at 600 mg and 2000 mg eprosartan / kg / day , respectively , for up to 2 years .", "label": "", "metadata": {}, "score": "59.317932"}
{"text": "b Response is related to baseline HbA1c .Treatment with AVANDARYL resulted in statistically significant improvements in FPG and HbA1c compared with each of the monotherapies .", "label": "", "metadata": {}, "score": "59.321423"}
{"text": "Cimetidine .Digoxin .Varenicline ( 1 mg twice daily ) did not alter the steady - state pharmacokinetics of digoxin administered as a 0.25 mg daily dose in 18 smokers .", "label": "", "metadata": {}, "score": "59.327362"}
{"text": "Nintedanib 200 mg + Afatinib 40 mg - Continuously .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 200 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 40 mg was given continuously once daily ( q.d . ) .", "label": "", "metadata": {}, "score": "59.389355"}
{"text": "Nintedanib 200 mg + Afatinib 40 mg - Continuously .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 200 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 40 mg was given continuously once daily ( q.d . ) .", "label": "", "metadata": {}, "score": "59.389355"}
{"text": "A total score ranged from 0 to 160 .A lower value corresponds to better well - being .Change From Baseline to 6 Months in Quality of Life ( QoL ) Assessed by Fatigue Impact Scale ( FIS ) Total Score - Part B [ Time Frame : Baseline ( week 0 ) , month 6 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "59.53305"}
{"text": "Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor agonists .Monitor serum lithium levels during concomitant use .", "label": "", "metadata": {}, "score": "59.659023"}
{"text": "This is a Phase IIa , open - label , randomized trial in treatment - na\u00efve , sputum smear - positive , subjects with pulmonary TB to assess the extended early bactericidal activity ( eEBA ) of TMC207 .", "label": "", "metadata": {}, "score": "59.699203"}
{"text": "Nintedanib 150 mg + Afatinib 40 mg - Continuously .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 150 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 40 mg was given continuously once daily ( q.d . ) .", "label": "", "metadata": {}, "score": "59.73127"}
{"text": "Nintedanib 150 mg + Afatinib 40 mg - Continuously .Patients receiving oral administration of soft - gelatine capsule of Nintedanib 150 mg continuously twice daily ( b.i.d . ) ; concomitantly , film - coated tablet of Afatinib 40 mg was given continuously once daily ( q.d . ) .", "label": "", "metadata": {}, "score": "59.73127"}
{"text": "Pharmacodynamics and Clinical Effects .Eprosartan inhibits the pharmacologic effects of angiotensin II infusions in healthy adult men .Single oral doses of eprosartan from 10 mg to 400 mg have been shown to inhibit the vasopressor , renal vasoconstrictive and aldosterone secretory effects of infused angiotensin II with complete inhibition evident at doses of 350 mg and above .", "label": "", "metadata": {}, "score": "59.817238"}
{"text": "It was conducted between 30 June 2011 and 21 December 2012 and recruited patients from 36 sites .Pre - Assignment Details .Significant events and approaches for the overall study following participant enrollment , but prior to group assignment .", "label": "", "metadata": {}, "score": "59.968388"}
{"text": "A single oral dose of 350 mg of eprosartan inhibits pressor effects by approximately 100 % at peak , with approximately 30 % inhibition persisting for 24 hours .", "label": "", "metadata": {}, "score": "60.038498"}
{"text": "Most adverse events were of mild or moderate severity and did not require discontinuation of therapy .The overall incidence of adverse experiences and the incidences of specific adverse events reported with eprosartan were similar to placebo .", "label": "", "metadata": {}, "score": "60.18045"}
{"text": "A dose - related increase in ERPF of 25 % to 30 % occurred in salt - restricted normal subjects , with the effect plateauing between the 200 mg and 400 mg doses .", "label": "", "metadata": {}, "score": "60.184444"}
{"text": "at 8 AM in the fasting state .The dose was the same as patients have had before entering the trial .Other Name : DuoCort .", "label": "", "metadata": {}, "score": "60.248116"}
{"text": "Both studies included three arms : naproxen and two doses of meloxicam .In both studies , meloxicam dosing began at 0.125 mg / kg / day ( 7.5 mg maximum ) or 0.25 mg / kg / day ( 15 mg maximum ) , and naproxen dosing began at 10 mg / kg / day .", "label": "", "metadata": {}, "score": "60.346924"}
{"text": "Minor elevations in creatinine and in BUN occurred in 0.6 % and 1.3 % , respectively , of patients taking Teveten \u00ae and 0.9 % and 0.3 % , respectively , of patients given placebo in controlled clinical trials .", "label": "", "metadata": {}, "score": "60.42038"}
{"text": "Eprosartan ( 1200 mg once daily for 7 days or 300 mg twice daily for 28 days ) had no effect on the excretion of uric acid in healthy men , patients with essential hypertension or those with varying degrees of renal insufficiency .", "label": "", "metadata": {}, "score": "60.462746"}
{"text": "Based on these results , MOBIC can be administered without regard to timing of meals or concomitant administration of antacids .Distribution .Meloxicam penetration into human red blood cells , after oral dosing , is less than 10 % .", "label": "", "metadata": {}, "score": "60.464874"}
{"text": "There were no significant differences in glimepiride pharmacokinetics between the 2 age groups .The mean AUC at steady state for the older patients was about 13 % lower than that for the younger patients ; the mean weight - adjusted clearance for the older patients was about 11 % higher than that for the younger patients .", "label": "", "metadata": {}, "score": "60.579376"}
{"text": "Original Secondary Outcome Measures ICMJE ( submitted : August 30 , 2007 ) .Assess the short term safety , tolerability and PK of multiple oral doses of TMC207 in treatment - na\u00c3 - ve subjects with pulmonary M.tuberculosis infection .", "label": "", "metadata": {}, "score": "60.695213"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "61.363777"}
{"text": "Peytavin G , Gautran C , Otoul C , et al .Lack of clinically relevant pharmacokinetic ( PK ) interaction between cetirazine ( CTZ ) and ritonavir in male healthy subjects .", "label": "", "metadata": {}, "score": "61.486637"}
{"text": "Oral bioavailability of varenicline is unaffected by food or time - of - day dosing .Metabolism / Elimination .The elimination half - life of varenicline is approximately 24 hours .", "label": "", "metadata": {}, "score": "61.57158"}
{"text": "Each dose of CHANTIX was given in two different regimens , with and without initial dose titration , to explore the effect of different dosing regimens on tolerability .", "label": "", "metadata": {}, "score": "61.604233"}
{"text": "Drug : Hydrocortisone , oral tablet , 10 mg .The reference drug was administered orally thrice daily ( at 8 AM , 12 AM and 4 PM ) .", "label": "", "metadata": {}, "score": "61.723007"}
{"text": "Gerber JG , Rosenkranz S , Segal Y , et al .Effect of ritonavir / saquinavir on stereoselective pharmacokinetics of methadone : results of AIDS clinical trials group ( ACTG ) 401 .", "label": "", "metadata": {}, "score": "61.935974"}
{"text": "In mice , the systemic exposure ( AUC ) to unbound eprosartan was approximately 25 times the exposure achieved in humans given 400 mg b.i.d . .", "label": "", "metadata": {}, "score": "61.947037"}
{"text": "In these subjects , meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time .However , one subject showed an increase in INR from 1.5 to 2.1 .", "label": "", "metadata": {}, "score": "62.09536"}
{"text": "Glimepiride : After intravenous ( IV ) dosing in normal subjects , the volume of distribution ( Vd ) was 8.8 L ( 113 mL / kg ) , and the total body clearance ( CL ) was 47.8 mL / min .", "label": "", "metadata": {}, "score": "62.09913"}
{"text": "The modified release hydrocortisone tablet was administered orally o.d .at 8 AM in the fasting state .Drug : hydrocortisone ( modified release ) , oral tablet 20 and 5 mg .", "label": "", "metadata": {}, "score": "62.562866"}
{"text": "During the Expansion Phase [ Time Frame : Tumour assessment was to be performed at Screening , every 6 weeks after starting study treatment until disease progression , and at the end - of - treatment ( EOT ) visit ( up to 1117 days ) ] .", "label": "", "metadata": {}, "score": "62.607594"}
{"text": "Subjects in treatment group D will receive 600 mg rifampin po q.d .daily for 7 days and subjects in treatment group E will receive 300 mg isoniazid po q.d .", "label": "", "metadata": {}, "score": "62.849556"}
{"text": "A higher value corresponds to better well - being .The SF-36 was a questionnaire used to assess physical functioning and is made up of eight domains : physical functioning , role physical , bodily pain , general health , vitality , social functioning , role - emotional and mental health .", "label": "", "metadata": {}, "score": "62.89193"}
{"text": "Subjects With Cardiovascular And Chronic Obstructive Pulmonary Disease .CHANTIX was evaluated in a randomized , double - blind , placebocontrolled study of subjects aged 35 to 75 years with stable , documented cardiovascular disease ( diagnoses other than , or in addition to , hypertension ) that had been diagnosed for more than 2 months .", "label": "", "metadata": {}, "score": "62.974133"}
{"text": "Whether this interaction also occurs with the IV , topical , or vaginal preparations of miconazole is not known .There is a potential interaction of glimepiride with inhibitors ( e.g. , fluconazole ) and inducers ( e.g. , rifampicin ) of cytochrome P450 2C9 .", "label": "", "metadata": {}, "score": "63.016823"}
{"text": "Agarwala S , Russo R , Mummaneni V , Randall D , et al .Steady state pharmacokinetic ( PK ) interaction study of atazanavir ( ATV ) with ritonavir ( RTV ) in healthy subjects .", "label": "", "metadata": {}, "score": "63.165577"}
{"text": "Discontinuing treatment with eprosartan does not lead to a rapid rebound increase in blood pressure .There was no change in mean heart rate in patients treated with eprosartan in controlled clinical trials .", "label": "", "metadata": {}, "score": "63.230415"}
{"text": "Reduced serum glucose values and degranulation of the pancreatic beta cells were observed in beagle dogs exposed to glimepiride 320 mg / kg / day for 12 months ( approximately 1,000 times the recommended human dose based on surface area ) .", "label": "", "metadata": {}, "score": "63.27578"}
{"text": "Cmax2 is the Cmax after second dose of study drug .The average of single and multiple dosing for combined arm 1 + 2 was reported .", "label": "", "metadata": {}, "score": "63.609425"}
{"text": "After 7 days , subjects in all treatment groups will receive appropriate anti - TB therapy according to national standards of country TB guidelines and culture and sensitivity results of the sputum specimens until clinical and microbiological cures have been achieved .", "label": "", "metadata": {}, "score": "63.751453"}
{"text": "Approximately 20 % of the radioactivity excreted in the urine was an acyl glucuronide of eprosartan with the remaining 80 % being unchanged eprosartan .Plasma protein binding of eprosartan is high ( approximately 98 % ) and constant over the concentration range achieved with therapeutic doses .", "label": "", "metadata": {}, "score": "63.883972"}
{"text": "One patient was withdrawn from clinical trials for leukopenia .No patient was withdrawn from any clinical trial for neutropenia .Four patients receiving Teveten \u00ae in clinical trials were withdrawn for thrombocytopenia .", "label": "", "metadata": {}, "score": "64.12337"}
{"text": "This monograph has been modified to include the generic and brand name in many instances .Key information relevant to the recruitment process for the overall study , such as dates of the recruitment period and locations .", "label": "", "metadata": {}, "score": "64.277504"}
{"text": "The extent of eprosartan plasma protein binding was not influenced by hepatic dysfunction .No dosage adjustment is necessary for patients with hepatic impairment ( see DOSAGE AND ADMINISTRATION ) .", "label": "", "metadata": {}, "score": "64.29558"}
{"text": "Since therapy should be individualized , no dose adjustments are necessary based on gender alone .Glimepiride : There were no differences between males and females in the pharmacokinetics of glimepiride when adjustment was made for differences in body weight .", "label": "", "metadata": {}, "score": "64.381836"}
{"text": "Eprosartan mesylate had no adverse effects on the reproductive performance of male or female rats at oral doses up to 1000 mg eprosartan / kg / day .", "label": "", "metadata": {}, "score": "64.42055"}
{"text": "There were too few black subjects to determine whether their response was similar to Caucasians .In general , blacks ( usually a low renin population ) have had smaller responses to ACE inhibitors and angiotensin II inhibitors than Caucasian populations .", "label": "", "metadata": {}, "score": "64.49005"}
{"text": "Renal elimination of varenicline is primarily through glomerular filtration along with active tubular secretion possibly via the organic cation transporter , OCT2 .Pharmacokinetics in Special Patient Populations .", "label": "", "metadata": {}, "score": "64.49422"}
{"text": "Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate .In vitro , methotrexate did not displace meloxicam from its human serum binding sites [ . see Drug Interactions ] .", "label": "", "metadata": {}, "score": "64.62831"}
{"text": "Osteoarthritisand Rheumatoid Arthritis .The use of MOBIC for the treatment of the signs and symptoms of osteoarthritis of the knee and hip was evaluated in a 12-week , double - blind , controlled trial .", "label": "", "metadata": {}, "score": "64.62984"}
{"text": "Cholestyramine : Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50 % .This resulted in a decrease in t 1/2 , from 19.2 hours to 12.5 hours , and a 35 % reduction in AUC .", "label": "", "metadata": {}, "score": "64.65255"}
{"text": "The CHANTIX dosage of 1 mg twice daily was achieved using a titration of 0.5 mg once daily for the initial 3 days followed by 0.5 mg twice daily for the next 4 days .", "label": "", "metadata": {}, "score": "64.729416"}
{"text": "Cmax1 is the Cmax after first dose of study drug .The average of single and multiple dosing for combined arm 1 + 2 was reported .", "label": "", "metadata": {}, "score": "64.91734"}
{"text": "In comparison , neither the AUC nor the C max values for meloxicam suspension were affected following a similar high fat meal , while mean T max values were increased to approximately 7 hours .", "label": "", "metadata": {}, "score": "64.92091"}
{"text": "Among the CHANTIX - treated patients enrolled in these studies , the completion rate was 65 % .Except for the dose - ranging study ( Study 1 ) and the maintenance of abstinence study ( Study 6 ) , patients were treated for 12 weeks and then were followed for 40 weeks post - treatment .", "label": "", "metadata": {}, "score": "65.12207"}
{"text": "CLINICAL PHARMACOLOGY .Mechanism of Action .The mechanism of action of meloxicam , like that of other NSAIDs , may be related to prostaglandin synthetase ( cyclo - oxygenase ) inhibition which is involved in the initial steps of the arachidonic acid cascade , resulting in the reduced formation of prostaglandins , thromboxanes and prostacylin .", "label": "", "metadata": {}, "score": "65.12627"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .Analysis used overall mITT analysis set ( all randomized patients who received at least 1 dose of double - blind study drug ) .", "label": "", "metadata": {}, "score": "65.4227"}
{"text": "M1 , but not M2 , possesses about 14 of the pharmacological activity as compared with its parent in an animal model ; however , whether the glucose - lowering effect of M1 is clinically meaningful is not clear .", "label": "", "metadata": {}, "score": "65.51065"}
{"text": "The bupropion SR quit rate was also superior to placebo .In addition , 29 % of the CHANTIX group were continuously abstinent from one week after TQD through the end of treatment as compared to 12 % of the placebo group and 23 % of the bupropion SR group .", "label": "", "metadata": {}, "score": "65.53825"}
{"text": "The bupropion SR quit rate was also superior to placebo .In addition , 29 % of the CHANTIX group were continuously abstinent from one week after TQD through the end of treatment as compared to 11 % of the placebo group and 21 % of the bupropion SR group .", "label": "", "metadata": {}, "score": "65.66683"}
{"text": "administered as capsules containing 300 mg rifampin ; 300 mg isoniazid po q.d .administered as tablets containing 300 mg isoniazid .Study Type ICMJE .", "label": "", "metadata": {}, "score": "65.72269"}
{"text": "Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide .Thus , no dosing adjustments are necessary during concomitant use with these agents .", "label": "", "metadata": {}, "score": "65.79034"}
{"text": "Rosiglitazone : Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease ( Child - Pugh Class B / C ) compared with healthy subjects .", "label": "", "metadata": {}, "score": "65.94589"}
{"text": "Glimepiride treatment did result in a slight , but statistically significant , decrease in the pharmacodynamic response to warfarin .The reductions in mean area under the prothrombin time ( PT ) curve and maximum PT values during glimepiride treatment were very small ( 3.3 % and 9.9 % , respectively ) and are unlikely to be clinically important .", "label": "", "metadata": {}, "score": "66.06667"}
{"text": "Penzak SR , Lawhorn WD , Hon YY , et al .Influence of ritonavir and CYP1A2 genotype on olanzapine disposition in healthy subjects [ abstract # A-493]. 41st", "label": "", "metadata": {}, "score": "66.40195"}
{"text": "Potential neonatal adverse effects include skull hypoplasia , anuria , hypotension , renal failure , and death .When pregnancy is detected , discontinue Teveten as soon as possible .", "label": "", "metadata": {}, "score": "66.433136"}
{"text": "Alternative Instructions For Setting A Quit Date .CHANTIX was evaluated in a double - blind , placebo - controlled trial where patients were instructed to select a target quit date between Day 8 and Day 35 of treatment .", "label": "", "metadata": {}, "score": "66.45264"}
{"text": "Burger DM , Hugen PWH , ter Hofstede , et al .Dose - finding study of a once daily indinavir / ritonavir regimen in healthy volunteers [ abstract # 321].", "label": "", "metadata": {}, "score": "66.51613"}
{"text": "The overall incidence of adverse events reported with Teveten \u00ae ( 54.4 % ) was similar to placebo ( 52.8 % ) .Facial edema was reported in 5 patients receiving eprosartan .", "label": "", "metadata": {}, "score": "66.5762"}
{"text": "Concomitant administration of eprosartan and digoxin had no effect on single oral - dose digoxin pharmacokinetics .Concomitant administration of eprosartan and warfarin had no effect on steady - state prothrombin time ratios ( INR ) in healthy volunteers .", "label": "", "metadata": {}, "score": "66.6745"}
{"text": "The expression of the insulin - regulated glucose transporter GLUT-4 was increased in adipose tissue .Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance .", "label": "", "metadata": {}, "score": "66.91037"}
{"text": "The PGWB consists of 22 self - administered items rated on a scale from 1 ( worst level of well - being ) to 6 ( maximum level of well - being ) with a total score ranging from 22 to 132 .", "label": "", "metadata": {}, "score": "67.093666"}
{"text": "Teveten \u00ae may be used in combination with other antihypertensive agents such as thiazide diuretics or calcium channel blockers if additional blood - pressure - lowering effect is required .", "label": "", "metadata": {}, "score": "67.21222"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00915343 Current Secondary Outcome Measures ICMJE ( submitted : July 2 , 2009 ) .", "label": "", "metadata": {}, "score": "67.51312"}
{"text": "Park JY , Kim KA , Kang MH , et al .Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects .Clin Pharmacol Ther 2004;75:157 - 162 .", "label": "", "metadata": {}, "score": "67.581055"}
{"text": "The sponsor can not require changes to the communication and can not extend the embargo .The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days .", "label": "", "metadata": {}, "score": "67.80679"}
{"text": "The sponsor can not require changes to the communication and can not extend the embargo .The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days .", "label": "", "metadata": {}, "score": "67.80679"}
{"text": "The Rac was calculated as area under the S - cortisol concentration versus time curve during a dosing interval at steady state ( AUCtau ) on Day 28 divided by AUC0 - 24h on Day 1 .", "label": "", "metadata": {}, "score": "67.88837"}
{"text": "Includes whether analysis was per protocol , intention to treat , or another method .Also provides relevant details such as imputation technique , as appropriate .", "label": "", "metadata": {}, "score": "68.05373"}
{"text": "The function of this parameter was to provide information about what percentage of the theoretical curve ( AUC0-inf ) was possible to determine experimentally ( AUC0-t ) .", "label": "", "metadata": {}, "score": "68.37819"}
{"text": "All studies enrolled almost equal numbers of men and women .The average age of patients in these studies was 43 years .Patients on average had smoked about 21 cigarettes per day for an average of approximately 25 years .", "label": "", "metadata": {}, "score": "68.44298"}
{"text": "Electrophysiology studies in vitro and neurochemical studies in vivo have shown that varenicline binds to \u03b1 4 \u03b2 2 neuronal nicotinic acetylcholine receptors and stimulates receptor - mediated activity , but at a significantly lower level than nicotine .", "label": "", "metadata": {}, "score": "68.59012"}
{"text": "Eprosartan was the only drug - related compound found in the plasma and feces .Following intravenous [ 14 C ] eprosartan , about 61 % of the material is recovered in the feces and about 37 % in the urine .", "label": "", "metadata": {}, "score": "68.716484"}
{"text": "Total drug plasma concentrations of meloxicam decreased and total clearance of meloxicam increased with the degree of renal impairment while free AUC values were similar in all groups .", "label": "", "metadata": {}, "score": "68.80385"}
{"text": "When these drugs are administered to a patient receiving glimepiride , the patient should be closely observed for loss of control .When these drugs are withdrawn from a patient receiving glimepiride , the patient should be observed closely for hypoglycemia .", "label": "", "metadata": {}, "score": "68.81987"}
{"text": "Hepatic Impairment .Due to the absence of significant hepatic metabolism , varenicline pharmacokinetics should be unaffected in patients with hepatic impairment .Drug - Drug Interactions .", "label": "", "metadata": {}, "score": "68.902405"}
{"text": "Rosiglitazone : The mean ( CV% ) oral volume of distribution ( Vss / F ) of rosiglitazone is approximately 17.6 ( 30 % ) liters , based on a population pharmacokinetic analysis .", "label": "", "metadata": {}, "score": "68.90591"}
{"text": "It consisted of 40 statements that measure fatigue in 3 areas : physical , cognitive , and psychosocial .This 40-item scale evaluates the construct of perceived impact of fatigue on everyday life .", "label": "", "metadata": {}, "score": "68.9351"}
{"text": "It consisted of 40 statements that measure fatigue in 3 areas : physical , cognitive , and psychosocial .This 40-item scale evaluates the construct of perceived impact of fatigue on everyday life .", "label": "", "metadata": {}, "score": "68.9351"}
{"text": "Meloxicam concentrations in synovial fluid , after a single oral dose , range from 40 % to 50 % of those in plasma .The free fraction in synovial fluid is 2.5 times higher than in plasma , due to the lower albumin content in synovial fluid as compared to plasma .", "label": "", "metadata": {}, "score": "69.127525"}
{"text": "[ see DOSAGE AND ADMINISTRATION , and Use In Specific Populations ] .Additionally , in subjects with ESRD , varenicline was efficiently removed by hemodialysis [ see OVERDOSAGE ] .", "label": "", "metadata": {}, "score": "69.16821"}
{"text": "Tran JQ , Petersen C , Garrett M , et al .Delavirdine ( DLV ) significantly increases exposure of low dose ritonavir ( RTV ) in healthy volunteers [ abstract # A-494]. 41st", "label": "", "metadata": {}, "score": "69.33675"}
{"text": "Day 1 ( Baseline ) and Week 18 .Safety Issue .No .Population Description .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "69.56302"}
{"text": "Renal Impairment : Rosiglitazone : There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis -dependent patients compared with subjects with normal renal function .", "label": "", "metadata": {}, "score": "69.569855"}
{"text": "No dosage adjustment is necessary in patients with mild to moderate renal impairment .Patients with severe renal impairment have not been adequately studied .The use of MOBIC in subjects with severe renal impairment is not recommended [ . see Warnings and Precautions and Use in Specific Populations ] .", "label": "", "metadata": {}, "score": "69.97537"}
{"text": "Urinary : albuminuria , cystitis , hematuria , micturition frequency , polyuria , renal calculus , urinary incontinence ; .Laboratory Test Findings .In placebo - controlled studies , clinically important changes in standard laboratory parameters were rarely associated with administration of Teveten \u00ae .", "label": "", "metadata": {}, "score": "70.01303"}
{"text": "Therefore , drugs that are cleared by renal secretion ( e.g. , metformin [ see below ] ) are unlikely to be affected by varenicline .", "label": "", "metadata": {}, "score": "70.0349"}
{"text": "Hematologic : anemia , purpura ; .Liver and Biliary : increased SGOT , increased SGPT ; .Metabolic and Nutritional : increased creatine phosphokinase , diabetes mellitus , glycosuria , gout , hypercholesterolemia , hyperglycemia , hyperkalemia , hypokalemia , hyponatremia ; .", "label": "", "metadata": {}, "score": "70.08774"}
{"text": "How large was the benefit with OD compared to TID and the responses were recorded as considerably poorer , somewhat poorer , comparable , large , very large ; 2 .", "label": "", "metadata": {}, "score": "70.62004"}
{"text": "Metabolism and Excretion .Rosiglitazone : Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine .The major routes of metabolism were Ndemethylation and hydroxylation , followed by conjugation with sulfate and glucuronic acid .", "label": "", "metadata": {}, "score": "70.81777"}
{"text": "The four primary endpoints were investigator 's global assessment , patient global assessment , patient pain assessment , and total WOMAC score ( a self - administered questionnaire addressing pain , function , and stiffness ) .", "label": "", "metadata": {}, "score": "70.82504"}
{"text": "There was an increase in both AUC ( 19 % ) and Cmax ( 55 % ) of glimepiride in the fed state compared with the fasted state .", "label": "", "metadata": {}, "score": "70.861755"}
{"text": "If oligohydramnios is observed , discontinue Teveten , unless it is considered lifesaving for the mother .Fetal testing may be appropriate , based on the week of pregnancy .", "label": "", "metadata": {}, "score": "70.96704"}
{"text": "The primary endpoint in this study was the ACR20 response rate , a composite measure of clinical , laboratory , and functional measures of RA response .", "label": "", "metadata": {}, "score": "71.128395"}
{"text": "von Moltke LL , Greenblatt DJ , Duan SX , et al .Inhibition of desipramine hydroxylation ( Cytochrome P450 - 2D6 ) in vitro by quinidine and by viral protease inhibitors : relation to drug interactions in vivo .", "label": "", "metadata": {}, "score": "71.163895"}
{"text": "In vitro data demonstrate that rosiglitazone is predominantly metabolized by cytochrome P450 ( CYP ) isoenzyme 2C8 , with CYP2C9 contributing as a minor pathway .", "label": "", "metadata": {}, "score": "71.43091"}
{"text": "One female and one male dog developed bilateral subcapsular cataracts .Non - GLP studies indicated that glimepiride was unlikely to exacerbate cataract formation .Evaluation of the co - cataractogenic potential of glimepiride in several diabetic and cataract rat models was negative and there was no adverse effect of glimepiride on bovine ocular lens metabolism in organ culture [ see ADVERSE REACTIONS ] .", "label": "", "metadata": {}, "score": "71.50302"}
{"text": "Hypotension in Volume- and/or Salt - Depleted Patients .In patients with an activated renin - angiotensin system , such as volume- and/or salt - depleted patients ( e.g. , those being treated with diuretics ) , symptomatic hypotension may occur .", "label": "", "metadata": {}, "score": "71.80973"}
{"text": "Smoking cessation itself may result in changes to warfarin pharmacokinetics [ see DRUG INTERACTIONS ] .Use with Other Drugs for Smoking Cessation .Bupropion : Varenicline ( 1 mg twice daily ) did not alter the steady - state pharmacokinetics of bupropion ( 150 mg twice daily ) in 46 smokers [ see DRUG INTERACTIONS ] .", "label": "", "metadata": {}, "score": "72.19874"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT02039245 Key information relevant to the recruitment process for the overall study , such as dates of the recruitment period and locations .", "label": "", "metadata": {}, "score": "72.521164"}
{"text": "Protein binding of meloxicam was not affected by hepatic impairment .No dosage adjustment is necessary in patients with mild to moderate hepatic impairment .Patients with severe hepatic impairment ( Child - Pugh Class III ) have not been adequately studied [ . see Warnings and Precautions and Use in Specific Populations ] .", "label": "", "metadata": {}, "score": "72.52506"}
{"text": "Rare cases of rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers .It can not be determined whether events were causally related to eprosartan : .", "label": "", "metadata": {}, "score": "72.73935"}
{"text": "No clinically meaningful pharmacokinetic drug - drug interactions have been identified .Also , in human hepatocytes in vitro , varenicline does not induce the cytochrome P450 enzymes 1A2 and 3A4 .", "label": "", "metadata": {}, "score": "72.9031"}
{"text": "Cardiovascular : angina pectoris , bradycardia , abnormal ECG , specific abnormal ECG , extrasystoles , atrial fibrillation , hypotension ( including orthostatic hypotension ) , tachycardia , palpitations ; .", "label": "", "metadata": {}, "score": "73.12822"}
{"text": "Approximately 40 % of the total radioactivity was recovered in feces and M1 and M2 ( predominant ) accounted for about 70 % of that recovered in feces .", "label": "", "metadata": {}, "score": "73.250015"}
{"text": "TMC207 treatment groups : 25 mg TMC207 po q.d ; 100 mg .TMC207 po q.d ; 400 mg TMC207 po q.d .; TMC207 will be administered as a 10 or 40 mg / mL oral solution .", "label": "", "metadata": {}, "score": "73.303215"}
{"text": "Transplantation 1999;68:307 - 9 .Penzak S , Shen J , Alfar R , Remaley A , Falloon J. Influence of low - dose ritonavir on the pharmacokinetics of the P - glycoprotein ( P - gp ) substrate digoxin .", "label": "", "metadata": {}, "score": "73.41657"}
{"text": "Inactive Ingredients .The 400 mg tablet contains the following : croscarmellose sodium , hypromellose , iron oxide red , iron oxide yellow , lactose monohydrate , magnesium stearate , microcrystalline cellulose , polyethylene glycol , polysorbate 80 , pregelatinized starch , and titanium dioxide .", "label": "", "metadata": {}, "score": "73.917435"}
{"text": "How strongly concur with the following statement : I prefer conventional TID to novel OD and the responses were recorded as strongly disagree , disagree , neutral , strongly , very strongly .", "label": "", "metadata": {}, "score": "74.07322"}
{"text": "The SF-36 was a questionnaire used to assess physical functioning and is made up of eight domains : physical functioning , role physical , bodily pain , general health , vitality , social functioning , role - emotional and mental health .", "label": "", "metadata": {}, "score": "74.56813"}
{"text": "Blockade of the AT 1 receptor removes the negative feedback of angiotensin II on renin secretion , but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effect of eprosartan on blood pressure .", "label": "", "metadata": {}, "score": "74.6301"}
{"text": "Morphometric measurement indicated that there was hypertrophy in cardiac ventricular tissues , which may be due to increased heart work as a result of plasma volume expansion .", "label": "", "metadata": {}, "score": "74.72446"}
{"text": "The major metabolites are the cyclohexyl hydroxy methyl derivative ( M1 ) and the carboxyl derivative ( M2 ) .Cytochrome P450 2C9 has been shown to be involved in the biotransformation of glimepiride to M1 .", "label": "", "metadata": {}, "score": "75.02338"}
{"text": "Eprosartan is eliminated by biliary and renal excretion , primarily as unchanged compound .Less than 2 % of an oral dose is excreted in the urine as a glucuronide .", "label": "", "metadata": {}, "score": "75.160645"}
{"text": "Cmax is a term that refers to the maximum ( or peak ) concentration that a drug achieves in the body after the drug has been administrated .", "label": "", "metadata": {}, "score": "75.24243"}
{"text": "The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells .", "label": "", "metadata": {}, "score": "75.4664"}
{"text": "Hemodialysis did not lower the total drug concentration in plasma ; therefore , additional doses are not necessary after hemodialysis .Meloxicam is not dialyzable [ . see Dosage and Administration , Warnings and Precautions , and Use in Specific Populations ] .", "label": "", "metadata": {}, "score": "75.517746"}
{"text": "Study 4 enrolled 1022 patients and Study 5 enrolled 1023 patients .Patients inappropriate for bupropion treatment or patients who had previously used bupropion were excluded .", "label": "", "metadata": {}, "score": "75.95874"}
{"text": "Nursing Mothers .Eprosartan is excreted in animal milk ; it is not known whether eprosartan is excreted in human milk .Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from eprosartan , a decision should be made whether to discontinue nursing or to discontinue the drug , taking into account the importance of the drug to the mother .", "label": "", "metadata": {}, "score": "76.30621"}
{"text": "About .Terms & Privacy .Connect .Subscribe to receive email notifications whenever new articles are published .This material is provided for educational purposes only and is not intended for medical advice , diagnosis or treatment .", "label": "", "metadata": {}, "score": "76.676796"}
{"text": "Eprosartan pharmacokinetics were not affected by concomitant administration of ranitidine .Eprosartan did not inhibit human cytochrome P450 enzymes CYP1A , 2A6 , 2C9/8 , 2C19 , 2D6 , 2E and 3A in vitro .", "label": "", "metadata": {}, "score": "77.1495"}
{"text": "TMC207-C202 : Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum - Smear Positive Tuberculosis .Official Title ICMJE .", "label": "", "metadata": {}, "score": "77.539345"}
{"text": "Respiratory : asthma , epistaxis ; .Skin and Appendages : eczema , furunculosis , pruritus , rash , maculopapular rash , increased sweating ; .", "label": "", "metadata": {}, "score": "77.75073"}
{"text": "NONCLINICAL TOXICOLOGY .Carcinogenesis , Mutagenesis , Impairment of Fertility .Mutagenesis : Meloxicam was not mutagenic in an Ames assay , or clastogenic in a chromosome aberration assay with human lymphocytes and an in vivo micronucleus test in mouse bone marrow .", "label": "", "metadata": {}, "score": "77.89336"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "78.24708"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "78.24708"}
{"text": "Eprosartan mesylate also did not cause structural chromosomal damage in vivo ( mouse micronucleus assay ) .In human peripheral lymphocytes in vitro , eprosartan mesylate was equivocal for clastogenicity with metabolic activation , and was negative without metabolic activation .", "label": "", "metadata": {}, "score": "78.57683"}
{"text": "Co- administration with inhibitors of OCT2 ( e.g. , cimeditine [ see below ] ) may not necessitate a dose adjustment of CHANTIX as the increase in systemic exposure to CHANTIX is not expected to be clinically meaningful .", "label": "", "metadata": {}, "score": "78.61081"}
{"text": "Each bottle of MOBIC oral suspension contains 7.5 mg meloxicam per 5 mL. Meloxicam is chemically designated as 4-hydroxy-2-methyl- N -(5-methyl-2-thiazolyl)-2 H -1,2-benzothiazine-3-carboxamide-1,1-dioxide .", "label": "", "metadata": {}, "score": "78.61839"}
{"text": "Nervous System / Psychiatric : anxiety , ataxia , insomnia , migraine , neuritis , nervousness , paresthesia , somnolence , tremor , vertigo ; .", "label": "", "metadata": {}, "score": "78.76074"}
{"text": "Study Phase .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Treatment Chantix . \"", "label": "", "metadata": {}, "score": "78.92804"}
{"text": "Excretion .Meloxicam excretion is predominantly in the form of metabolites , and occurs to equal extents in the urine and feces .Only traces of the unchanged parent compound are excreted in the urine ( 0.2 % ) and feces ( 1.6 % ) .", "label": "", "metadata": {}, "score": "79.205124"}
{"text": "Meloxicam has pKa values of 1.1 and 4.2 .MOBIC is available as a tablet for oral administration containing 7.5 mg or 15 mg meloxicam , and as an oral suspension containing 7.5 mg meloxicam per 5 mL. The inactive ingredients in MOBIC tablets include colloidal silicon dioxide , crospovidone , lactose monohydrate , magnesium stearate , microcrystalline cellulose , povidone , and sodium citrate dihydrate .", "label": "", "metadata": {}, "score": "79.590485"}
{"text": "Teveten - Clinical Pharmacology .Mechanism of Action .Angiotensin II ( formed from angiotensin I in a reaction catalyzed by angiotensin - converting enzyme [ kininase II ] ) , a potent vasoconstrictor , is the principal pressor agent of the renin - angiotensin system .", "label": "", "metadata": {}, "score": "79.8029"}
{"text": "Activation of PPARy nuclear receptors regulates the transcription of insulin - responsive genes involved in the control of glucose production , transport , and utilization .", "label": "", "metadata": {}, "score": "80.05006"}
{"text": "Rosiglitazone .Rosiglitazone improves glycemic control by improving insulin sensitivity .Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferatoractivated receptor - gamma ( PPARy ) .", "label": "", "metadata": {}, "score": "80.18288"}
{"text": "Based on responses to the Brief Questionnaire of Smoking Urges and the Minnesota Nicotine Withdrawal scale \" urge to smoke \" item , CHANTIX reduced urge to smoke compared to placebo .", "label": "", "metadata": {}, "score": "80.91519"}
{"text": "Because the safety and effectiveness of CHANTIX in pediatric patients have not been established , CHANTIX is not recommended for use in patients under 18 years of age .", "label": "", "metadata": {}, "score": "80.9304"}
{"text": "Eprosartan does not exhibit any partial agonist activity at the AT 1 receptor .Its affinity for the AT 1 receptor is 1,000 times greater than for the AT 2 receptor .", "label": "", "metadata": {}, "score": "81.19111"}
{"text": "Rosiglitazone .Drugs That Inhibit , Induce , or are Metabolized by Cytochrome P450 : In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations .", "label": "", "metadata": {}, "score": "81.97063"}
{"text": "Chantix .CLINICAL PHARMACOLOGY .Mechanism Of Action .Varenicline binds with high affinity and selectivity at \u03b1 4 \u03b2 2 neuronal nicotinic acetylcholine receptors .", "label": "", "metadata": {}, "score": "82.07239"}
{"text": "Mobic News .DESCRIPTION .Meloxicam , an oxicam derivative , is a member of the enolic acid group of nonsteroidal anti - inflammatory drugs ( NSAIDs ) .", "label": "", "metadata": {}, "score": "82.950134"}
{"text": "Eprosartan blocks the vasoconstrictor and aldosterone - secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor found in many tissues ( e.g. , vascular smooth muscle , adrenal gland ) .", "label": "", "metadata": {}, "score": "85.0323"}
{"text": "In vitro testing found no protein binding drug interaction between digoxin and meloxicam .Lithium : In a study conducted in healthy subjects , mean pre - dose lithium concentration and AUC were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg twice daily with meloxicam 15 mg QD every day as compared to subjects receiving lithium alone [ . see Drug Interactions ] .", "label": "", "metadata": {}, "score": "85.447235"}
{"text": "IAS Conference on HIV Pathogenesis and Treatment ; 2001 July 8 - 11 ; Buenos Aires , Argentina .Kilby JM , Sfakianos G , Gizzi N , et al .", "label": "", "metadata": {}, "score": "87.1793"}
{"text": "Teveten Description .Teveten \u00ae ( eprosartan mesylate ) is a non - biphenyl non - tetrazole angiotensin II receptor ( AT 1 ) antagonist .", "label": "", "metadata": {}, "score": "87.27285"}
{"text": "AUC between specified timepoints included AUC0 - 4h , AUC4 - 12h , AUC6 - 12h , AUC12 - 24h , AUC0 - 10h , AUC4 - 10h , AUC6 - 10h , AUC10 - 24h , AUC(0-inf ) , AUC(24h - inf ) .", "label": "", "metadata": {}, "score": "88.31977"}
{"text": "T\u00bd ( h ) .Tmax ( h ) .Data presented as geometric mean ( range ) , except T\u00bd which is presented as arithmetic mean ( range ) and Tmax , which is presented as median ( range ) .", "label": "", "metadata": {}, "score": "88.760284"}
{"text": "Metabolism .Meloxicam is extensively metabolized in the liver .Meloxicam metabolites include 5'-carboxy meloxicam ( 60 % of dose ) , from P-450 mediated metabolism formed by oxidation of an intermediate metabolite 5'-hydroxymethyl meloxicam which is also excreted to a lesser extent ( 9 % of dose ) .", "label": "", "metadata": {}, "score": "88.80727"}
{"text": "42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ; 2002 September 27 - 30 ; San Diego , California .Piscitelli S , Bechtel C , Sadler B , et al .", "label": "", "metadata": {}, "score": "89.17556"}
{"text": "7th Conference on Retroviruses and Opportunitic Infections ; 2000 January 30-February 4 ; San Francisco , California .Kurowski M , Staszewski S , Arslan A , et al .", "label": "", "metadata": {}, "score": "89.241974"}
{"text": "Its structural formula is : .Eprosartan mesylate is a white to off - white free - flowing crystalline powder that is insoluble in water , freely soluble in ethanol , and melts between 248 \u00b0 C and 250 \u00b0 C . .", "label": "", "metadata": {}, "score": "89.89491"}
{"text": "International Conference on AIDS .1996 Jul 7 - 12 ; Vancouver , Canada .Sheikh AM , Wolf DC , Lebovics E , et al .", "label": "", "metadata": {}, "score": "90.324615"}
{"text": "42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ; 2002 September 27 - 30 ; Chicago , Illinois .CDC .Guidelines for the use of antiretroviral agents in HIV - infected adults and adolescents .", "label": "", "metadata": {}, "score": "90.771996"}
{"text": "Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed .Restriction Description : Boehringer Ingelheim ( BI ) acknowledges that investigators have the right to publish the study results .", "label": "", "metadata": {}, "score": "94.090546"}
{"text": "NSCLC .This is a part of the \" expansion phase \" which follows on the dose - escalation phase .Pancreatic Adenocarcinoma .This is a part of the \" expansion phase \" which follows on the dose - escalation phase .", "label": "", "metadata": {}, "score": "101.41722"}
{"text": "NSCLC .This is a part of the \" expansion phase \" which follows on the dose - escalation phase .Pancreatic Adenocarcinoma .This is a part of the \" expansion phase \" which follows on the dose - escalation phase .", "label": "", "metadata": {}, "score": "101.41722"}
{"text": "Its empirical formula is C 14 H 13 N 3 O 4 S 2 and it has the following structural formula : .Meloxicam is a pastel yellow solid , practically insoluble in water , with higher solubility observed in strong acids and bases .", "label": "", "metadata": {}, "score": "102.46547"}
